



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** bpgoffice@wjgnet.com  
**https://**www.wjgnet.com

## PEER-REVIEW REPORT

**Name of journal:** World Journal of Gastroenterology

**Manuscript NO:** 62252

**Title:** Genotype 3-hepatitis C virus' last line of defense

**Reviewer's code:** 04762027

**Position:** Peer Reviewer

**Academic degree:** PhD

**Professional title:** Postdoc

**Reviewer's Country/Territory:** United Kingdom

**Author's Country/Territory:** Poland

**Manuscript submission date:** 2021-01-11

**Reviewer chosen by:** Ya-Juan Ma

**Reviewer accepted review:** 2021-01-12 12:30

**Reviewer performed review:** 2021-01-12 14:20

**Review time:** 1 Hour

<b>Scientific quality</b>	<input checked="" type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input checked="" type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
**https://**[www.wjgnet.com](http://www.wjgnet.com)

#### **SPECIFIC COMMENTS TO AUTHORS**

Congratulations to the author on presenting a manuscript that provides an exhaustive list of therapies on the HCV arena, especially genotype 3. For a non-clinician reader, this manuscript would be a useful one to read and understand the impact of DAAs on the HCV treatment.



## PEER-REVIEW REPORT

**Name of journal:** World Journal of Gastroenterology

**Manuscript NO:** 62252

**Title:** Genotype 3-hepatitis C virus' last line of defense

**Reviewer's code:** 05466134

**Position:** Peer Reviewer

**Academic degree:** MBBS, MD

**Professional title:** Academic Fellow

**Reviewer's Country/Territory:** United States

**Author's Country/Territory:** Poland

**Manuscript submission date:** 2021-01-11

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2021-01-14 12:40

**Reviewer performed review:** 2021-01-14 20:09

**Review time:** 7 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** bpgoffice@wjgnet.com  
**https://**www.wjgnet.com

## **SPECIFIC COMMENTS TO AUTHORS**

It was a pleasure reviewing this paper written by Dorota Zarębska-Michaluk. The author has provided an precise review of the available literature regarding treatment of Genotype 3 HCV infection. All references were cross checked and were appropriately used. The relation between hepatic steatosis and GT3 infection was explained with appropriate use of references. In the current DAA era, GT-3 has emerged as the most difficult GT to treat. Mayvret and Eplclusa are the initial treatment options for patients that are treatment Naïve without and with cirrhosis, whereas Eplclusa is preferred for retreatment in patients without cirrhosis and Mavyret or Vosevi in patients with cirrhosis. This paper will be interesting to the readers, and especially who are interested in knowing the pathway that lead to development of these new strategies for treatment of HCV-GT-3 infection. Following are some minor comments. The core tip has similar sentences as the abstract. Recommend summarizing and rephrasing the sentences to give uniqueness to the core tip section rather than copying information from the abstract already available to the readers. Recommend using more appropriate terminologies. Consider replacing words like "good one", "bad one" or "naughty one". Correction: old: "there is a still room for improvement" new: "there is still room for improvement" Please spell out abbreviation CHC in following sentence "The strong association between GT3 infection and end-stage liver disease was documented in HCV-infected drug abusers in France and confirmed by a population-based study in a cohort of native Alaskans with CHC[30,31]." Please spell out abbreviation SoC in following sentence: The addition of SOF to pegIFN $\alpha$  and RBV (SPR) leads to better outcomes when compared to SoC, regardless of liver fibrosis and history of previous antiviral therapy. I hope these comments help author to improve their manuscript.